109 related articles for article (PubMed ID: 30903421)
21. An evaluation of the performance of SCORE Sweden 2015 in estimating cardiovascular risk: The Northern Sweden MONICA Study 1999-2014.
Karjalainen T; Adiels M; Björck L; Cooney MT; Graham I; Perk J; Rosengren A; Söderberg S; Eliasson M
Eur J Prev Cardiol; 2017 Jan; 24(1):103-110. PubMed ID: 27708071
[TBL] [Abstract][Full Text] [Related]
22. Impacts of chronic kidney disease and diabetes on cardiovascular mortality in a general Japanese population: A 20-year follow-up of the NIPPON DATA90 study.
Hirata A; Okamura T; Sugiyama D; Kuwabara K; Kadota A; Fujiyoshi A; Miura K; Okuda N; Ohkubo T; Okayama A; Ueshima H;
Eur J Prev Cardiol; 2017 Mar; 24(5):505-513. PubMed ID: 27856810
[TBL] [Abstract][Full Text] [Related]
23. Residual lifetime risk of cardiovascular diseases in Japan.
Turin TC; Rumana N; Okamura T
J Atheroscler Thromb; 2011; 18(6):443-7. PubMed ID: 21512278
[TBL] [Abstract][Full Text] [Related]
24. The Impending Epidemic of Cardiovascular Diseases in Patients With Cancer in Japan.
Okura Y; Ozaki K; Tanaka H; Takenouchi T; Sato N; Minamino T
Circ J; 2019 Oct; 83(11):2191-2202. PubMed ID: 31534064
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome.
Glintborg D; Rubin KH; Nybo M; Abrahamsen B; Andersen M
Cardiovasc Diabetol; 2018 Mar; 17(1):37. PubMed ID: 29519249
[TBL] [Abstract][Full Text] [Related]
26. Partial cancer prevalence in Japan up to 2020: estimates based on incidence and survival data from population-based cancer registries.
Tabata N; Ohno Y; Matsui R; Sugiyama H; Ito Y; Tsukuma H; Oshima A
Jpn J Clin Oncol; 2008 Feb; 38(2):146-57. PubMed ID: 18245517
[TBL] [Abstract][Full Text] [Related]
27. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project.
Hori M; Matsuda T; Shibata A; Katanoda K; Sobue T; Nishimoto H;
Jpn J Clin Oncol; 2015 Sep; 45(9):884-91. PubMed ID: 26142437
[TBL] [Abstract][Full Text] [Related]
28. How many people will need palliative care in 2040? Past trends, future projections and implications for services.
Etkind SN; Bone AE; Gomes B; Lovell N; Evans CJ; Higginson IJ; Murtagh FEM
BMC Med; 2017 May; 15(1):102. PubMed ID: 28514961
[TBL] [Abstract][Full Text] [Related]
29. Geographical Variation in Underlying Social Deprivation, Cardiovascular and Other Comorbidities in Patients with Potentially Curable Cancers in England: Results from a National Registry Dataset Analysis.
Waterhouse JV; Welch CA; Battisti NML; Sweeting MJ; Paley L; Lambert PC; Deanfield J; de Belder M; Peake MD; Adlam D; Ring A
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e708-e719. PubMed ID: 37741712
[TBL] [Abstract][Full Text] [Related]
30. Physician cardiovascular disease risk factor management: practice analysis in Japan versus the USA.
Schuster RJ; Zhu Y; Ogunmoroti O; Terwoord N; Ellison S; Fujiyoshi A; Ueshima H; Muira K
Qual Prim Care; 2013; 21(1):51-60. PubMed ID: 23735635
[TBL] [Abstract][Full Text] [Related]
31. Risk of Cardiovascular Disease Associated with a Restless Legs Syndrome Diagnosis in a Retrospective Cohort Study from Kaiser Permanente Northern California.
Van Den Eeden SK; Albers KB; Davidson JE; Kushida CA; Leimpeter AD; Nelson LM; Popat R; Tanner CM; Bibeau K; Quesenberry CP
Sleep; 2015 Jul; 38(7):1009-15. PubMed ID: 26083613
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of diabetes in Japanese patients with cancer.
Saito E; Goto A; Kanehara R; Ohashi K; Noda M; Matsuda T; Katanoda K
J Diabetes Investig; 2020 Sep; 11(5):1159-1162. PubMed ID: 32022988
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for cardiovascular disease in Canada.
Tanuseputro P; Manuel DG; Leung M; Nguyen K; Johansen H;
Can J Cardiol; 2003 Oct; 19(11):1249-59. PubMed ID: 14571310
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database.
Tuppin P; Rivière S; Rigault A; Tala S; Drouin J; Pestel L; Denis P; Gastaldi-Ménager C; Gissot C; Juillière Y; Fagot-Campagna A
Arch Cardiovasc Dis; 2016; 109(6-7):399-411. PubMed ID: 27079468
[TBL] [Abstract][Full Text] [Related]
35. Modeling the burden of cardiovascular disease in Turkey.
Balbay Y; Gagnon-Arpin I; Malhan S; Öksüz ME; Sutherland G; Dobrescu A; Villa G; Ertuğrul G; Habib M
Anatol J Cardiol; 2018 Oct; 20(4):235-240. PubMed ID: 30297582
[TBL] [Abstract][Full Text] [Related]
36. Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.
Young JB; Gauthier-Loiselle M; Bailey RA; Manceur AM; Lefebvre P; Greenberg M; Lafeuille MH; Duh MS; Bookhart B; Wysham CH
Cardiovasc Diabetol; 2018 Aug; 17(1):118. PubMed ID: 30143045
[TBL] [Abstract][Full Text] [Related]
37. Statistics of soft-tissue sarcoma in Japan: Report from the Bone and Soft Tissue Tumor Registry in Japan.
Ogura K; Higashi T; Kawai A
J Orthop Sci; 2017 Jul; 22(4):755-764. PubMed ID: 28601416
[TBL] [Abstract][Full Text] [Related]
38. [Estimation of the future epidemiological situation of tuberculosis in Japan].
Ohmori M; Yoshiyama T; Ishikawa N
Kekkaku; 2008 Apr; 83(4):365-77. PubMed ID: 18516900
[TBL] [Abstract][Full Text] [Related]
39. Visualization of Cancer and Cardiovascular Disease Co-Occurrence With Network Methods.
Duarte CW; Lindner V; Francis SA; Schoormans D
JCO Clin Cancer Inform; 2017 Nov; 1():1-12. PubMed ID: 30657376
[TBL] [Abstract][Full Text] [Related]
40. Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study.
Laleman N; Henrard S; van den Akker M; Goderis G; Buntinx F; Van Pottelbergh G; Vaes B
BMC Cardiovasc Disord; 2018 Nov; 18(1):209. PubMed ID: 30400778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
